rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RCUS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Caught Out By Arcus Biosciences' Slide? Here's What Bears Saw

      Arcus Biosciences kept reporting promising kidney cancer data and a long cash runway, yet long-term holders still saw their capital shrink. For Arcus Biosciences shareholders, the loss from the start of the year was 29.6%, including dividends. If you had been weighing an investment back on 2026-01-01, looking at bullish price targets on one side and concerns about regulatory risk and partner dependence on the other, which signals would have deserved the most attention? A Narrative on Simply...

      8h agoYahoo FinanceRCUS
      Arcus Biosciences at Jefferies Global Healthcare Conference: casdatifan push
      Nov 16Investing.comJEFRCUS
      Arcus Biosciences stock hits 52-week low at $17.43
      Nov 13Investing.comRCUS
      Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
      Nov 4Yahoo FinanceRCUS
      Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates
      Nov 4Investing.comRCUS
      Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
      Nov 4Yahoo FinanceRCUS
      Earnings To Watch: Arcus Biosciences Inc (RCUS) Q3 2026 -- GF Value Sees 80% Downside
      Nov 3Yahoo FinanceRCUS
      Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
      Nov 2Yahoo FinanceJEFRCUS
      Arcus Biosciences Announces New Employment Inducement Grants
      Oct 26Yahoo FinanceRCUS
      How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale
      Oct 24Yahoo FinanceRCUS
      Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

      Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock today, the key question is whether the current share price is reasonable when compared with the revenue Arcus is generating. Over the past 5 years the share price has fallen 44.6%, which puts the spotlight firmly on whether the business now justifies its market value through its sales profile. New kidney cancer data...

      Oct 24Yahoo FinanceRCUS
      Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy - Slideshow (NYSE:RCUS) 2026-10-22
      Oct 22Seeking AlphaRCUS
      Why is Arcus Biosciences stock sliding today?
      Oct 22Investing.comRCUS
      Arcus Biosciences prices $250 million stock offering at $17.50
      Oct 22Investing.comRCUS
      Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
      Oct 22Yahoo FinanceRCUS
      Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)
      Oct 21Seeking AlphaRCUS
      Arcus Biosciences stock falls on public offering announcement
      Oct 21Investing.comRCUS
      Arcus Biosciences launches public offering of common stock
      Oct 21Investing.comRCUS
      Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
      Oct 21MorningstarRCUS
      Arcus Biosciences Announces Commencement of Public Offering of Common Stock
      Oct 21Yahoo FinanceRCUS
      Truist raises Arcus Biosciences stock price target on drug data
      Oct 21Investing.comRCUS
      Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
      Oct 21Yahoo FinanceRCUS
      Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS)
      Oct 21Seeking AlphaRCUS
      Wedbush Adjusts Price Target on Arcus Biosciences to $49 From $43, Keeps Outperform Rating
      Oct 21Yahoo FinanceRCUS
      Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
      Oct 21Yahoo FinanceRCUS
      Arcus stock rises on ARC-20 data for kidney cancer drug (RCUS)
      Oct 20Seeking AlphaRCUS
      Arcus Dips, But Recovers Steep Losses, On Merck-Rivaling News

      Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, but shares took a swim.

      Oct 20Investor's Business DailyMRKRCUS
      Why is Arcus Biosciences stock sliding today?
      Oct 20Investing.comRCUS
      Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
      Oct 20Yahoo FinanceRCUS
      Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
      Oct 20Yahoo FinanceRCUS
      William Blair Initiates Arcus Biosciences at Outperform
      Oct 16Yahoo FinanceRCUS
      William Blair initiates Arcus Biosciences stock with outperform rating
      Oct 16Investing.comRCUS
      JPMorgan initiates Arcus Biosciences stock at Overweight, $41 target
      Oct 14Investing.comRCUS
      Arcus Biosciences Announces New Employment Inducement Grants
      Oct 9Yahoo FinanceRCUS
      Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?
      Oct 6Yahoo FinanceRCUS
      Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)

      Detailed price information for Arcus Biosciences Inc (RCUS-N) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailSTTKEHCRCUS
      How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

      Arcus Biosciences recently announced it would host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-line clear cell renal cell carcinoma treatment settings. A particularly important aspect is the breadth of casdatifan data, including TKI-free first-line combinations, long-follow-up second-line cabozantinib combinations, and translational HIF-2a...

      Oct 5Yahoo FinanceRCUS
      Arcus Biosciences Announces New Employment Inducement Grants

      HAYWARD, Calif., September 24, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $26.39, which was the closi

      Sep 24Yahoo FinanceRCUS
      Cantor Fitzgerald reiterates Arcus Biosciences stock rating
      Sep 22Investing.comRCUS
      Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
      Sep 22Yahoo FinanceRCUS
      Arcus Biosciences stock gains on TD Cowen buy rating
      Sep 16Investing.comRCUS
      Why is Arcus Biosciences stock rallying today?
      Sep 16Investing.comRCUS
      Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug
      Sep 16Investing.comRCUS
      TD Cowen Initiates Arcus Biosciences at Buy

      Arcus Biosciences (RCUS) has an average rating of buy and mean price target of $39.27, according to

      Sep 16Yahoo FinanceCRBURCUS
      Cantor Fitzgerald reiterates Arcus Biosciences stock rating
      Sep 11Investing.comRCUS
      Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS)

      Detailed price information for Cooper Companies (COO-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailBWAYRCUS
      Arcus Biosciences at cantor global healthcare conference: casdatifan in focus
      Sep 10Investing.comRCUS
      Arcus Biosciences at Citi summit: casdatifan data loom large
      Sep 9Investing.comRCUS
      Arcus Biosciences Announces New Employment Inducement Grants

      HAYWARD, Calif., September 09, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company’s common stock at an exercise price per share of $29.06, which was t

      Sep 9Yahoo FinanceRCUS
      Truist raises Arcus Biosciences stock price target on trial data
      Sep 8Investing.comRCUS

      This is the newest page. Registered accounts read further back.